

# BMJ Open Evaluation of patient-reported outcome measurements as a reliable tool to measure acceptability of the taste of paediatric medicines in an inpatient paediatric population

Punam Mistry,<sup>1</sup> Heather Stirling,<sup>2</sup> Claire Callens,<sup>3</sup> James Hodson,<sup>4</sup> Hannah Batchelor,<sup>1</sup> On behalf of SPaeDD-UK project

**To cite:** Mistry P, Stirling H, Callens C, *et al.* Evaluation of patient-reported outcome measurements as a reliable tool to measure acceptability of the taste of paediatric medicines in an inpatient paediatric population. *BMJ Open* 2018;**8**:e021961. doi:10.1136/bmjopen-2018-021961

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-021961>).

Received 8 February 2018  
Revised 2 May 2018  
Accepted 25 May 2018



<sup>1</sup>School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham, UK

<sup>2</sup>Paediatrics, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK

<sup>3</sup>NIHR Clinical Research Network West Midlands, Institute of Research and Development, Birmingham, UK

<sup>4</sup>Institute of Translational Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK

## Correspondence to

Dr Hannah Batchelor;  
[h.k.batchelor@bham.ac.uk](mailto:h.k.batchelor@bham.ac.uk)

## ABSTRACT

**Objective** To evaluate the age appropriateness and suitability of patient-reported outcome measures to assess the acceptability of the taste of oral liquid medicines in children.

**Design and setting** An observational mixed-methods study involving children aged 2–16 years taking oral liquid medicine in paediatric inpatient wards across the West Midlands (UK). Assessment tools included patient-reported scores on the taste of medicines via a five-point Facial Hedonic Scale; a Visual Analogue Scale (VAS); a question, ‘Did you think the medicine tasted OK?’ and researcher observations of facial expressions and behaviours immediately before, during and after administration.

**Results** 611 children participated. The percent unable to complete the scales was 7% (n=46) for the VAS; 2% (n=15) for the hedonic scale and 1% (n=7) for the question about taste. Significant correlations (Spearman’s r) were observed between the patient-reported outcome measures: 0.80 and 0.78 for the taste question and hedonic and VAS, respectively, and 0.84 for the hedonic and VAS. Researcher observations demonstrated the ability of the patient to take the medicine as intended but did not provide sensitive measures of taste. 5% of administrations were not taken as intended by the children. Medicines known to have poor taste (clarithromycin and prednisolone) showed mean hedonic and VAS scores of  $\geq 3.5$  and  $>65$  mm, respectively.

**Conclusions** Patient-reported outcome measures correlate with each other and are a useful means to assess the taste (and acceptability) of medicines. Hedonic scales are better understood by children and should be the first choice tool in the assessment of medicines taste.

## INTRODUCTION

Measurement of acceptability of paediatric medicines is important for two major reasons: (1) poor acceptability is likely to be associated with poor compliance and therefore suboptimal therapy; (2) regulatory guidelines dictate that paediatric medicines’ acceptability should be assessed (preferably

## Strengths and limitations of this study

- This is the first study to compare methodologies to assess the acceptability of taste of liquid medicines in a large UK-based paediatric population aged 2–16 years.
- The sample size in this study provided large data sets of six key medicines, which provides a representative comparison for newly developed products.
- This study was conducted within an inpatient environment and the acceptance of taste of medicines in a domiciliary environment may differ.
- The study design captured the most relevant aspects of acceptability of taste while minimising the burden to participants, it was not possible to measure every aspect. Suggestions for future research include measurement of: impact of the devices used to administer medicines; use of alternative hedonic scales (eg, those with two to nine faces); alternative anchor phrases; an endpoint of neutral and not positive within a hedonic scale; further exploration of medicines that tasted OK as well as those with a reported negative taste.

in children).<sup>1</sup> Patient acceptability has been defined as, ‘an overall ability of the patient and caregiver (defined as ‘user’) to use a medicinal product as intended (or authorised)’.<sup>1</sup> A major barrier in the assessment of acceptability and subsequent interpretation of results is the lack of guidance on how an acceptability test should be conducted and the criteria used to determine acceptability in children.<sup>2</sup> It is unlikely that a single acceptability test will be valid for all medicines, due to the need to consider the benefit–risk balance on an individual basis.

Taste was previously identified as the biggest barrier in adherence and compliance in a paediatric population.<sup>3</sup> Previous techniques to evaluate acceptability focused on taste and

were based on methodology adapted from sensory analysis undertaken in the food industry. A variety of scales have been used to measure the acceptability of medicines, yet it remains unclear whether any of the scales is better for a particular purpose with regard to validity, reliability, feasibility and preference.<sup>4 5</sup> Patient-reported measures of taste offer a pragmatic means to collect data on products. However, there is often concern about the reliability of these measures, particularly in a paediatric population.<sup>6</sup> Sensory analysis is commonly used to show a preference for one product over another, but this is not always relevant to medicines as often there is no alternative available. In addition, it can be rationalised that the therapeutic benefits of medicines outweigh the negative taste. It is complex to distinguish between acceptability and likeability of a medicine's taste, yet this difference may be critical for appropriate interpretation of resulting data.

The validity of any new method relies on how well it compares to other measures.<sup>7</sup> The development of a reliable method to assess the taste of medicines requires comparison of a variety of tools. This study compares a range of methods to assess the taste of medicines within a large paediatric inpatient population. Independent researcher observations are also compared with the self-reported data. The results of this study will be used to propose a suitable method that can be used for future taste assessments.

## MATERIALS AND METHODS

Three patient-reported outcome (PRO) measures were compared with each other, and to researcher observations


of medicines administration in an observational mixed-methods study.

### Patient and public involvement

Bespoke PRO tools were developed for this study based on previous methodologies and in consultation with the National Institute for Health Research Children Specialty's Young Person's Advisory Group (West Midlands).<sup>8</sup> The young people (aged 11–18 years) reviewed the tools and provided feedback that the tools were age appropriate. The same young people provided feedback on the trial materials including information sheets and how to minimise the burden to participants during the conduct of the study. The results are available to participants as a poster summary from the corresponding author's personal webpage ([www.hannahbatchelor.com](http://www.hannahbatchelor.com)); this poster was also reviewed by the young person's group.

### PRO measures used

The hedonic scale selected was a genderless image where the mouth was the only expressive facial feature (see figure 1A). The images were yellow to ensure they stood out from the background paper. They were obtained from S-cool the revision website (<http://www.s-cool.co.uk/gcse/food-technology/systems-and-control/revise-it/sensory-evaluation> (accessed December 2015)). Children and young people preferred simple faces and felt that this would be most appropriate for the youngest age group<sup>8</sup>; anchor phrases were not included on the hedonic scale to keep this tool basic. The Visual Analogue Scale (VAS) included anchor phrases selected by the young persons' group as the most clear and relevant,<sup>8</sup> these were used at the extreme ends of the continuous scale.

<b>A</b>	Circle the face that describes the taste of the medicine you have just had?
	
<b>B</b>	How much did you like the taste of your medicine? Put a cross on the line below.
<div style="display: flex; justify-content: space-between; align-items: center;"> <span>0</span> <span>10</span> </div> <div style="display: flex; justify-content: space-between; align-items: center;"> <span>I really liked it</span> <span>I didn't like it at all</span> </div>	
<b>C</b>	Did you think the medicine tasted OK? Please circle.
<div style="display: flex; justify-content: space-around;"> <span>Yes</span> <span>No</span> <span>Not Sure</span> </div>	

**Figure 1** Scales used within PRO tools completed by paediatric participants immediately after administration of their medicine. (A) Hedonic scale; (B) Anchored Visual Analogue Scale; (C) direct question on taste. PRO, patient-reported outcome.

The direction of change was from positive to negative, which corresponds to the extensive data on hedonic scales used for pain assessment in children.<sup>9</sup> Previous studies in adult studies of foods showed no difference based on structural variations that read from positive to negative or vice versa.<sup>10</sup>

The third PRO was a question, 'Did you think the medicine tasted OK?' with the response options of: yes, no, not sure.

### Participants and setting

Paediatric inpatients aged between 2 and 16 years taking any oral liquid medicine as part of their medical care were recruited using convenience sampling, from inpatient wards at 11 sites across the West Midlands. Informed consent was obtained from the parent or legal guardian of the participating child and for children over 12 years of age assent was also required. The study was conducted between December 2015 and April 2016.

Demographic information was obtained on participant's age and whether this was their first dose of the medicine under evaluation. The medicine name, brand, manufacturer, concentration (strength), dose administered and product batch number were recorded.

Each participant was observed by a researcher as they took their medicine. Some medicines were provided to the patient as an oral liquid following extemporaneous preparation within the clinical setting, for example, dispersion of prednisolone tablets immediately prior to dosing. Depending on the capability of the child, the medicines were either self-administered, or administered by nursing staff and/or parents. Participants were asked

not to mix the medicine with any other food product, as this might influence the participant's responses.

### PRO tools

Participants were asked to complete (1) five-point Facial Hedonic Scale and (2) 10cm VAS (figure 1A,B immediately after administration of their medicine; both scales were provided on separate paper documents in a randomised order. Children were free to ask for support in completing the questionnaires from parents, nursing staff or the researcher present. The cognitive function of children was not assessed and age may not always predict a child's ability to complete the questionnaire; therefore, all children were free to ask for support if required. Both reporting documents included a third PRO (figure 1C) as a question, 'Did you think the medicine tasted OK?' with the response options of: yes, no, not sure. The purpose behind this question was to endorse the reliability of the participant's reporting from both scale-based questionnaires.

The data from the scales (figure 1A,B) were transformed into numbers for subsequent statistical analysis. Hedonic expressions were converted to scores of 1–5 with 1 being the most positive expression and 5 the most negative. VAS scores were reported as measurements from the extreme left hand side of the scale in millimetre; this provided scores of 0–100 mm (although scale was written as 0–10 cm).

### Researcher observations

A facial expression and behavioural scale to capture researcher observations was a 12-point tick chart designed

Facial expressions observed			
Expression	Tick if observed prior to administration	Tick if observed during administration	
Eyes squeezed shut or towards shut			
Brow bulge/lower (frown)			
Nose wrinkle			
Pursed lips			
Behaviours observed			
Behaviour	Tick if observed prior to administration	Tick if observed during administration	
Child refuses medicine			=unacceptable
Child cries/screams			=unacceptable
Child requires physical restraint			=unacceptable
Child voices resistance			=unacceptable
	Tick if observed immediately after administration		
Child voices disgust			=unacceptable
Child vomits			=unacceptable
Child spits out medicine			=unacceptable
Child cries			=unacceptable

**Figure 2** Researcher observation sheet completed by the researcher prior to, during and post medicine administration.

in-house (figure 2), based on an existing scale used to measure behavioural distress in children undergoing medical procedures,<sup>11</sup> the Procedural Behavior Rating Scale (PBRs). The PBRs was developed specifically for infants and children with cancer, who were undergoing bone marrow aspirations or lumbar punctures. It contained 13 behavioural codes including: cry, cling, pain verbal, flail, stall, scream, refuse position, restrain, emotional support, muscular rigidity and requests termination.<sup>11</sup> The in-house tool was based on this scale plus, other scales used to measure behavioural distress in children.<sup>12</sup> The facial expressions included on the scale were derived from previous studies that assessed food liking in children based on their facial expressions; typically negative tastes are associated with eyes squeezing, brow bulge, nose wrinkle and pursed lips.<sup>13</sup>

A series of nine short films or still pictures of children were made available to researchers participating in the study to assess the inter-rater agreement in the facial expressions displayed.

### Statistical analysis

A sample size was not fixed for this study at the outset as there was no appropriate power calculation. Advice from a statistician was to ensure we had sufficient numbers (<50) paired data to ensure that selectivity and sensitivity of the methods could be demonstrated.

Initially, the mean age of participants who were unable to understand the assessments were compared with those who could using Mann-Whitney U tests. The same approach was also used to compare the scores for patients receiving their first dose, relative to those who had previously received the medicine. Age was then divided into categories, and the proportions of participants scoring in the extreme categories for the scales were compared using Fisher's exact tests. Spearman's correlation coefficients were used to assess the degree of correlation between the assessments for the cohort as a whole, and within each of the age categories. In this analysis, the 'Did you think the medicine tasted OK?' question was treated as an ordinal scale, with the response of Don't Know being between Yes and No. Where responses were not recorded for all criteria, the outcome was calculated based on those that were available.

The assessments were then dichotomised, and compared using McNemar's tests to assess for marginal homogeneity in the 2x2 tables, and Kappa to assess agreement. The three assessments were then combined into a composite score, which was compared with reported behaviours using Kendall's tau correlation coefficients. All analyses were performed using IBM SPSS V.22 (IBM), and  $p < 0.05$  deemed to be indicative of statistical significance throughout.

## RESULTS AND DISCUSSION

Data were available for 628 administrations to 611 children aged between 2 and 16 years. The median participant

age was 6 years. Further details on the distribution of the participant ages can be found in online supplementary material 1.

To ease analysis of data, the population for this study was stratified by age into three groups: 2–4 years ( $n=237$ ), 5–9 years ( $n=227$ ) and 10–16 years ( $n=147$ ).

The medicine was administered as the first dose in 162 cases. There was no evidence of a significant difference in the hedonic or VAS scores between those receiving their first dose of a medicine, compared with those who had previous administrations ( $p=0.336$ ,  $0.909$ , respectively). For all subsequent analysis, the data were pooled for those receiving their first and subsequent doses of medicine.

### Completeness of patient-reported assessment scales

The assessment scales were not completed by all of the study participants. The VAS had the lowest completion rate, where 46 (7%) were not completed due to lack of understanding by the child, compared with 15 (2%) for the hedonic scale. There were 7 (1%) cases where the child did not understand the question, 'Did you think the medicine taste OK?'. The range and mean age of those unable to complete the scales were 2–5 years with a mean of 2.4 years for the hedonic; 2–6 years with a mean of 3.1 years for the VAS and 2–3 years with a mean of 2.3 years for the taste question. In each case, participants unable to understand the assessment methods were significantly younger than the remainder of the cohort ( $p < 0.001$  each assessment). The cognitive function of children was not assessed within this study and there was an assumption of cognitive normal for age for all participants.

### Distribution of responses to patient-reported assessment scales


In the patient-reported scales (VAS and hedonic), the responses tended to be biased towards the extreme responses, with 56% of responses being in the highest or lowest categories for hedonic score (figure 3A) and, 55% within 1 cm from either end of the scale in the VAS (figure 3B).

The use of the extreme ends of the scales was greater in the younger populations ( $p < 0.001$ ) (data are shown in online supplementary material 2). For those that completed the hedonic scale, 64% of those aged 2–4 years used the extreme ends of the scale compared with 60% of those aged 5–9; 35% of those aged 10–16 years. A similar trend was observed in the VAS data where 66% of those aged 2–4 years were within 10 mm of either end of the scale compared with 60% of those aged 5–9 years and 39% of those aged 10–16 years.

### Reliability of assessment, 'Did you think the medicine tasted OK?'

The question, 'Did you think the medicine tasted OK?' was asked to participants on two occasions for each medicine administration; once following the hedonic and once following the VAS (which were presented in a randomised order). In the 600 cases, where participants responded





**Figure 3** Hedonic and Visual Analogue Scale (VAS) score distribution.

to both questions, the same response was given in 569 (95%) of cases, giving a Kappa statistic of 0.91. In cases where the answers were not consistent, the median age of the respondents was 5 years (mean age=6.3 years). For subsequent analysis, the two versions of this question were merged, with discrepancies resolved by taking the most positive response given by the participant.

#### Correlation between PRO measures

Significant correlations were observed between the hedonic scale score, VAS and ‘Did you think the medicines tasted OK?’ question (all  $p < 0.001$  table 1), with the strongest correlation observed between the hedonic and VAS scores (Spearman’s  $r = 0.84$ ). The weakest correlations were consistently observed in the youngest patients (age 2–4 years), implying that this group of patients had

**Table 1** Spearman’s  $r$  correlation values between patient-reported outcome measures

	‘Tastes OK’ versus hedonic	‘Tastes OK’ versus VAS	Hedonic versus VAS
<b>Overall</b>	<b>0.80</b>	<b>0.78</b>	<b>0.84</b>
<b>Age (years)</b>			
2–4	0.77	0.68	0.76
5–9	0.83	0.85	0.90
10–16	0.80	0.81	0.86

VAS, Visual Analogue Scale.

the lowest consistency in scores given across the different assessments. However, despite this, the consistency between the scores was still reasonable, with correlation coefficients ranging from 0.68 to 0.77.

The assessments were dichotomised, to identify those responses that classified a medicine as tasting acceptable. For the hedonic scale, this was defined as a neutral to positive response (the leftmost three faces of figure 1A). For the ‘Did you think the medicine tasted OK?’ question, grouping the ‘yes’ and ‘not sure’ responses was considered most appropriate, as the overall purpose is the assessment of acceptability of taste of a medicine; the response ‘no’ is clearly aligned to an unacceptable taste, making other responses acceptable. The level of agreement between the resulting dichotomised scores was high (90%), with a Kappa statistic of 0.782 and no indication of bias (McNemar’s test:  $p = 0.519$ ).

Correlation of the hedonic scale to the ‘tastes OK’ question is simple; however, interpretation of the VAS is more complex. The VAS had anchor phrases at either end to maintain the continuous scale, so it was not obvious where neutral or positive was ranked on the scale. Initially, an arbitrary cut-off of  $< 50$  mm in the VAS was used to define acceptability, which gave reasonable agreement with both the dichotomised hedonic (88%) and ‘tastes OK’ (86%) measures. However, McNemar’s test indicted significant bias in both cases ( $p < 0.001$ ), with a tendency for the VAS score of 0–50 mm to underestimate the number of tastes-acceptable responses, compared with the hedonic and ‘tastes OK’ assessments. As a result, alternative VAS cut-offs were explored, with 0–70 mm selected to approximately match the cut-off on the hedonic scale where the neutral face becomes the negative. Using 70 mm rather than 50 mm in the VAS marginally increased the agreement with both the dichotomised hedonic and ‘tastes OK’ measures to 91% but, more importantly, eliminated the previously observed bias (McNemar’s test  $p = 1.000$ , 0.683, respectively). All subsequent analysis used the cut-off of  $> 70$  mm as a measure of unacceptable taste.

#### Associations with researcher observations and PRO measures

One patient did not have a record of facial expression/behaviours, hence they were excluded, and the analysis was based on  $n = 620$  cases. Associations between facial expressions and behaviours (listed in figure 2) were

**Table 2** Relationship between facial expression or a behaviour and a patient report of an unacceptable tasting medicine

Behaviour	Cases where taste was reported as unacceptable (n=255)		Tau	Sens. (%)	Spec. (%)
	Not displayed (%)	Displayed (%)			
Voices disgust	160/515 (31)	95/105 (90)	0.45	37	97
Eyes squeezed	131/460 (28)	124/160 (78)	0.44	49	90
Nose wrinkle	125/433 (29)	130/187 (70)	0.38	51	84
Voices resistance	184/539 (34)	71/81 (88)	0.37	28	97
Refusal	192/551 (35)	63/69 (91)	0.36	25	98
Pursed lips	168/505 (33)	87/115 (76)	0.33	34	92
Cries/screams	201/559 (36)	54/61 (89)	0.32	21	98
Brow bulge	149/463 (32)	106/157 (68)	0.31	42	86
Physical restraint	219/579 (38)	36/41 (88)	0.25	14	99
Cries	216/573 (38)	39/47 (83)	0.24	15	98
Spits out	229/590 (39)	26/30 (87)	0.21	10	99
Vomits	248/613 (40)	7/7 (100)	0.13	3	100

linked to cases where the medicines were reported to have an unacceptable taste, based on a composite outcome (table 2). This was defined using the criteria defined previously. Where responses were not recorded for all criteria, the outcome was calculated based on those that were available. In total, 255/620 (41%) of assessments identified the taste of medicines to be unacceptable. The associations between this outcome, and the various facial expressions and behaviours that were recorded were then assessed.

Table 2 shows the incidence of the facial expression or behaviour as a fraction of the total population. The behaviours are listed in order of Kendall's tau correlation coefficients, with those behaviours most strongly associated with unacceptable taste having the highest value of tau. Based on this metric, voicing disgust was the behaviour most strongly associated with negative taste. Of the 105 patients who voiced disgust, 95 (90%) reported the taste of the medicine to be negative. This rate was almost threefold higher than the 160/515 (31%) who reported negative taste after not voicing disgust. Ordering the data in this way puts 'vomits' in last place, despite the fact that 100% of patients who vomited found the taste

of their medicine to be unacceptable. Since so few children vomited (n=7), the proportion of the total number of children who identified the taste as unacceptable and also displayed this behaviour (ie, the sensitivity) was low, at 3%. Hence, although a vomiting child is almost certain to find the taste unacceptable, using this behaviour in isolation as a predictor of negative taste would miss the vast majority of patients who reported taste to be negative.

Inter-rater agreement assessed via the use of short films and images were mixed; prevalent expressions were detected in >95% of cases, whereas some mild expressions were only detected in 40%–50% of those viewing the images.

### Analysis of medicine-specific taste assessment

Fifty-seven different drugs were observed in this study and the six most commonly administered were paracetamol, ibuprofen, prednisolone, co-amoxiclav, amoxicillin and clarithromycin, which made up 76% (n=477) of the total data set.

Comparisons were made across the six most commonly prescribed drugs. Table 3 ranks these drugs in order of taste, and reports the means scores on the hedonic scale

**Table 3** Patient-reported taste scores by medicine

Drug	Hedonic score		VAS score		Tastes OK? (% 'No')	Composite outcome % unacceptable
	Mean	% unacceptable	Mean (mm)	% unacceptable		
Clarithromycin (n=26)	3.5	62	70	58	65	77
Prednisolone (n=86)	3.6	58	68	54	61	70
Amoxicillin (n=30)	2.7	37	37	23	33	43
Co-amoxiclav (n=50)	2.5	30	39	24	29	33
Paracetamol (n=193)	2.4	22	37	21	21	29
Ibuprofen (n=92)	2.1	14	27	12	12	20

**Table 4** Percentage unable to take medicine as intended

Medicine	% spat out/ vomited the medicine	Composite outcome % unacceptable
Clarithromycin (n=26)	23	77
Amoxicillin (n=30)	13	43
Prednisolone (n=86)	9	70
Co-amoxiclav (n=50)	6	33
Ibuprofen (n=92)	2	20
Paracetamol (n=193)	1	29

and VAS, as well as the proportion of patients answering 'no' to the, 'Did you think the medicine tasted OK?' question.

The drugs can be divided into three groups based on these data: clarithromycin and prednisolone were found to be the worst tasting; amoxicillin and co-amoxiclav were mid-range, and ibuprofen and paracetamol were the best tasting medicines. The effect of brand was also investigated and the data are presented in online supplementary material 3.

In addition to reports of taste, the proportion of children who refused, vomited or spat out the medicines, was calculated and classified as unable to 'use a medicinal product as intended'. In total, this occurred in 33/620 (5%) administrations, which are reported for the six most commonly used drugs in table 4.

Clarithromycin was the most commonly not taken as intended and was also the drug most frequently identified as having unacceptable taste, based on the previously defined composite outcome. However, there was insufficient data to suggest that the taste of the medicine was directly related to the ability to take the medicine as intended. Children may vomit due to their underlying illness rather than as a direct result of the taste of their medicine.

## DISCUSSION

Few studies have categorised acceptability of the taste of medicines. The results within this study agree with previous reports, where a neutral to positive hedonic response indicates acceptable taste<sup>14–17</sup>; Sjövall *et al*<sup>18</sup> compared two brands of penicillin and reported that the acceptable taste mean hedonic score was within the neutral to positive range and an unacceptable taste was in the negative range.<sup>18</sup> Children were free to ask for support in completing the PRO measured and we did not collect data on how many received help in this aspect; it would be of value to consider how many, particularly in the youngest age group received support. Many of the children aged 2–5 years were able to provide reliable data on the taste of medicines demonstrating that the scales and questions used within this study are suitable for very young participants.

## Interpretation of facial expressions and behaviours

Voicing disgust was the behaviour most strongly associated with unacceptable taste while, perhaps counterintuitively, vomiting was the behaviour least strongly correlated with unacceptable taste. Despite the fact that 100% of patients who vomited found the taste of their medicine to be unacceptable, only a small number of patients vomited (n=7). As a result, while vomiting was a highly specific predictor of unacceptable taste, it had very low sensitivity. A similar pattern was also observed for the other facial expressions and behaviours, with sensitivity ranging from 10% to 51%, and specificity from 84% to 99%. This can be interpreted as indicating that, while it was uncommon to observe these facial expressions and behaviours in patients who found the taste of the medicine acceptable, displaying facial expressions and behaviours was not a strong indicator of unacceptability.

The behaviours used to inform the researcher observations were not always clearly defined; for example, the use of physical restraint was not explicitly stated and further work is required to better understand what physical restraint may be considered acceptable.

The explicit definition of an acceptable medicine being 'an overall ability of the patient and caregiver (defined as 'user') to use a medicinal product as intended (or authorised)',<sup>19</sup> includes the patient/caregiver's ability to access the medicine and comply with packaging requirements and for this study to demonstrate that the medicine was swallowed without incident. In total, 33/620 (5%) of medicines were spat out or vomited, and therefore unacceptable within this in patient population. This demonstrates that, although some of the behaviour and expressions observed may link more strongly to a negative taste, they do not automatically mean that the medicine was unacceptable.

In future studies, observations should ensure that the medicine was taken as intended; this may require a simple tool to ensure that the dose was completely swallowed without spitting out or vomiting. There is no need to include additional observations, as these were not strongly correlated to PROs on the taste of medicines.

## Medicine-specific taste assessment

Our results correlate well with other reports in the literature on the taste of medicines. Both paracetamol and ibuprofen have previously been reported to demonstrate acceptable taste (mid-range in a five-point hedonic scale) in paediatric populations.<sup>20–21</sup> Co-amoxiclav and amoxicillin were reported to have acceptable taste to 57%–67% of children within this study, which is consistent with previous literature, which has reported co-amoxiclav to be preferred to other antibiotics in terms of taste, including amoxicillin.<sup>22–28</sup> Previous work suggested that 60% of children accepted amoxicillin without problems and 63% of children liked the taste of co-amoxiclav.<sup>28</sup> Prednisolone and clarithromycin were the least liked medicines, again consistent with published data, with results showing predominantly negative scores in hedonic scales or the

equivalent of >70 mm in a VAS.<sup>3 24 29–33</sup> This study identified differences in acceptance of certain brands of medicines; however, there was insufficient sample numbers to undertake a detailed analysis of the impact of brand on taste and acceptance. A future study that explored brand preference would be of value to patients and those purchasing commonly used medicines.

Using our criteria, the proportion of patients classifying taste as acceptable for the most liked of the frequently prescribed medicines (ibuprofen and paracetamol) was over 70%; the proportion classifying taste as acceptable for the least liked medicines (prednisolone and clarithromycin) was less than 30%. This study provides some standardised values for medicines used within a UK population, the thresholds reported here provide guidance for future medicines development where in addition to taste scores the overall risk–benefit of the medicine will need to be considered.

### Recommended tools to assess acceptability

This study has correlated three simple patient-reported measures of medicines taste acceptability. It has also provided comparative data from existing medicines. Regulations mandate that all new medicines need to be demonstrated to be acceptable to children.<sup>1</sup> This study provides pragmatic and reliable tools to conduct this assessment. Furthermore, comparison of the results from a new medicine using these tools can be directly compared with existing medicines to support evidence of acceptance.

## CONCLUSIONS

This study has generated data on the taste of medicines commonly used in paediatric populations aged 2–16 years. The results of this study suggest that PRO measures are a reliable and valid assessment of the taste of children's medicines, for children aged from 2 to 16 years. These assessment tools offer a mechanism to evaluate the taste of other medicines (either novel products and formulations or medicines used orally in an off-label or unlicensed manner) to generate comparative data on the taste of medicines.

The data from this study coupled with previous literature on the taste of medicines provides evidence to suggest criteria to demonstrate acceptability of taste of medicines.

Our results suggest that criteria to demonstrate acceptability of taste are: a mean VAS score of <70 mm; a mean hedonic score of ≤3 (neutral or positive face) and a non-negative response to the 'Tastes OK?' question. Pragmatically, there is no need to use all methods. As the hedonic scale was understood across the widest age range, this should be the first choice method going forwards.

It would be prudent to ensure that any new product exceeds these scores to demonstrate that it is likely to have acceptable taste in practice.

**Acknowledgements** The authors would like to thank the NIHR Clinical Research Network: West Midlands–Young Person's Steering Group (YPSG) for their input and advice in the development, conduct and dissemination of this study. All patients, families and researchers at the participating sites are acknowledged for their participation in this study.

**Contributors** PM contributed to the acquisition, analysis and interpretation of the data. HS contributed to the design, acquisition, analysis and interpretation of the data and revising the manuscript following reviewers' comments. CC contributed to the design of the study and acquisition of the data. JH contributed to the design, statistical analysis and interpretation of the data and revising the manuscript following reviewers' comments. HB contributed to the design, acquisition, analysis and interpretation of the data and revising the manuscript following reviewers' comments. She is the corresponding author for this work.

**Funding** This work was conducted as part of the SPaeDD-UK project (Smart Paediatric Drug Development–UK, a project cofunded by Innovate UK and the contributing companies of AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Juniper Pharmaceuticals and Pfizer. (<http://www.paediatricscienceuk.com>).

**Competing interests** None declared.

**Patient consent** Not required.

**Ethics approval** Ethical approval was granted by London Surrey Borders Ethical Committee (REC reference: 15/LO/1253; IRAS project ID: 179684).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Additional data are available in the online supplementary files. The full data set is held by the corresponding author, please email with any requests for extra data.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

## REFERENCES

1. EMA. Guideline on pharmaceutical development of medicines for paediatric use EMA/CHMP/QWP/805880/2012. London. 2013 [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2013/07/WC500147002.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf) (accessed 18 Jun 2017).
2. Mistry P, Batchelor H. SPaeDD-UK project (Smart Paediatric Drug Development - UK). Evidence of acceptability of oral paediatric medicines: a review. *J Pharm Pharmacol* 2017;69:361–76.
3. Venables R, Batchelor H, Hodson J, *et al.* Determination of formulation factors that affect oral medicines acceptability in a domiciliary paediatric population. *Int J Pharm* 2015;480:55–62.
4. Davies EH, Tuleu C. Medicines for children: a matter of taste. *J Pediatr* 2008;153:599–604.
5. Mistry P, Batchelor H. SPaeDD-UK project. Methodology Used to Assess Acceptability of Oral Pediatric Medicines: A Systematic Literature Search and Narrative Review. *Paediatr Drugs* 2017;19:223–33.
6. Matza LS, Patrick DL, Riley AW, *et al.* Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. *Value Health* 2013;16:461–79.
7. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. *Health Qual Life Outcomes* 2006;4:79.
8. Mistry P, Batchelor H, Tibbins C. Design of methodological tools to assess acceptability of paediatric medicines. *Int J Pharm* 2016;511:1143–4.



9. Tomlinson D, von Baeyer CL, Stinson JN, *et al.* A systematic review of faces scales for the self-report of pain intensity in children. *Pediatrics* 2010;126:e1168–98.
10. Peryam DR, Pilgrim FJ. Hedonic scale method of measuring food preferences. *Food Technology* 1957;11:9–14.
11. Katz ER, Kellerman J, Siegel SE. Behavioral distress in children with cancer undergoing medical procedures: developmental considerations. *J Consult Clin Psychol* 1980;48:356–65.
12. Blount RL, Loiselle KA. Behavioural assessment of pediatric pain. *Pain Res Manag* 2009;14:47–52.
13. Forestell CA, Mennella JA. More than just a pretty face. The relationship between infant's temperament, food acceptance, and mothers' perceptions of their enjoyment of food. *Appetite* 2012;58:1136–42.
14. Motte J, Pedespan JM, Sevestre M, *et al.* Acceptabilité et tolérance du valproate de sodium, granules à libération prolongée, en monothérapie chez l'enfant épileptique à partir de trois ans. *Archives de Pédiatrie* 2005;12:1533–9.
15. Mulla H, Buck H, Price L, *et al.* 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. *J Oncol Pharm Pract* 2016;22:387–95.
16. Schwartz RH. Enhancing children's satisfaction with antibiotic therapy: A taste study of several antibiotic suspensions. *Current Therapeutic Research* 2000;61:570–81.
17. Thompson A, Reader S, Field E, *et al.* Open-label taste-testing study to evaluate the acceptability of both strawberry-flavored and orange-flavored amylmetacresol/2,4-dichlorobenzyl alcohol throat lozenges in healthy children. *Drugs R D* 2013;13:101–7.
18. Sjövall J, Fogh A, Huitfeldt B, *et al.* Methods for evaluating the taste of paediatric formulations in children: a comparison between the facial hedonic method and the patients' own spontaneous verbal judgement. *Eur J Pediatr* 1984;141:243–7.
19. Kozarewicz P. Regulatory perspectives on acceptability testing of dosage forms in children. *Int J Pharm* 2014;469:245–8.
20. Reader S, Shaw H, Hails S. A taste-testing study in healthy volunteers (children) to investigate children's preference for ibuprofen or placebo suspension. *Paediatr Perinat Drug Ther* 2006;7:54–8.
21. Smith CJ, Sammons HM, Fakis A, *et al.* A prospective study to assess the palatability of analgesic medicines in children. *J Adv Nurs* 2013;69:655–63.
22. Angelilli ML, Toscani M, Matsui DM, *et al.* Palatability of oral antibiotics among children in an urban primary care center. *Arch Pediatr Adolesc Med* 2000;154:267–70.
23. Gooch WM, Philips A, Rhoades R, *et al.* Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. *Pediatr Infect Dis J* 1997;16:S21–4.
24. Matsui D, Lim R, Tschen T, *et al.* Assessment of the palatability of beta-lactamase-resistant antibiotics in children. *Arch Pediatr Adolesc Med* 1997;151:599–602.
25. Powers JL, Gooch WM, Oddo LP. Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients. *Pediatr Infect Dis J* 2000;19(12 Suppl):S174–80.
26. Toscani M, Dreihobl M, Freed J, *et al.* A multicenter, randomized, comparative assessment in healthy pediatric volunteers of the palatability of oral antibiotics effective in the therapy of otitis media. *Current Therapeutic Research* 2000;61:278–85.
27. Ubaka CM, Udeogaranya OP, Ezeugwu N. Palatability of oral paediatric antibiotics commonly prescribed in a Nigerian specialist hospital: Table 1. *European Journal of Hospital Pharmacy* 2013;20:122–4.
28. Dagan R, Shvartzman P, Liss Z. Variation in acceptance of common oral antibiotic suspensions. *Pediatr Infect Dis J* 1994;13:686–90.
29. Hames H, Seabrook JA, Matsui D, *et al.* A palatability study of a flavored dexamethasone preparation versus prednisolone liquid in children with asthma exacerbation in a pediatric emergency department. *Canadian Journal of Clinical Pharmacology* 2008;15:e95–e8.
30. Isa JM, Wong GK, Teraoka SS, *et al.* Parental pediatric corticosteroid preferences. *Am J Emerg Med* 2001;19:29–31.
31. Kim MK, Yen K, Redman RL, *et al.* Vomiting of liquid corticosteroids in children with asthma. *Pediatr Emerg Care* 2006;22:397–401.
32. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. *Pediatr Infect Dis J* 1996;15:30–7.
33. Stafford L, Hope ME, Janney EP, *et al.* Comparison of paediatric steroid mixtures. *The Australian Journal of Hospital Pharmacy* 1998;28:246–9.